Paper Details

  1. Home
  2. Paper Details

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.

Author: ChenLi, FanLinjun, HeCheng, JiangJun, LiangYan, QiXiaowei, RenLin, TanXuanni, TangPeng, WangMinghao, XuhongJuncheng, YanWenting, ZhangFan, ZhangYi, ZhongLing

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pyrotinib, a new drug, has shown promise as a neoadjuvant therapy for HER2-positive breast cancer. This study found that pyrotinib combined with other chemotherapy drugs was effective and safe in treating HER2-positive breast cancer. Further research is needed to confirm these findings.
Paper Details　
Original Abstract of the Article :
This is the first trial to explore the neoadjuvant therapy of pyrotinib in HER2-positive operable and locally advanced breast cancer, in combination with epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab. Results primarily showed that pyrotinib in combination with epirubicin pl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108050/

データ提供：米国国立医学図書館（NLM）

Neoadjuvant Therapy: A New Oasis in the Treatment of HER2-Positive Breast Cancer

Breast cancer research is constantly evolving, seeking new and effective treatments. This study explores the potential of neoadjuvant therapy using pyrotinib, a novel drug, in combination with existing treatments for HER2-positive breast cancer. The study employs a Phase II clinical trial design to evaluate the safety and efficacy of this combination therapy.

A Promising Oasis: Pyrotinib in Neoadjuvant Therapy for HER2-Positive Breast Cancer

The results of this study provide compelling evidence that pyrotinib, in combination with epirubicin, cyclophosphamide, docetaxel, and trastuzumab, is effective and safe in the treatment of HER2-positive operable and locally advanced breast cancer. This finding offers a glimmer of hope for patients with this challenging disease, paving the way for future research and clinical trials.

New Horizons in Breast Cancer Treatment: Hope for the Future

The study's findings suggest that pyrotinib could be a valuable addition to the arsenal of treatments available for HER2-positive breast cancer. While further research is needed, these early results hold promise for improving outcomes for patients with this disease. The study emphasizes the importance of continued innovation and exploration in the quest for better treatments for breast cancer. Like a camel seeking a new oasis in the vast desert, researchers are constantly searching for new solutions to improve the lives of those affected by this disease.

Dr. Camel's Conclusion

This study is like a beacon of hope in the vast desert of breast cancer research. Pyrotinib's potential as a neoadjuvant therapy offers a new path forward for patients with HER2-positive breast cancer. This research reminds us that the pursuit of better treatments is an ongoing journey, requiring constant exploration and innovation to discover new oases of hope for those facing this disease.
Date :
  1. Date Completed 2021-06-21
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

33000490

DOI: Digital Object Identifier

PMC8108050

Related Literature

Article Analysis
・Side Effects of epirubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.